The direct cardioprotective effects of GLP-1(2836) do not depend on the GLP-1R
Reports from the European Medicines Agency (EMA) were due in November 2023, but the EMA asked for more data from manufacturers in December 2023, and final results are still unreleased [11, 31]
The risks of taking any compounded GLP-1s include: Medication that contains too little or too much of the active ingredient A product that contains no active ingredients at all Dosing errors when taking the medication Adverse reactions How to be a smart consumer when it comes to compounded GLP-1s Compounded GLP-1s can vary in strength, effectiveness and quality, so they should only be taken under the guidance of a healthcare provider (HCP)
These are selected and dosed based on individual lab results (including IGF-1 levels), symptoms, age, goals, and clinical profile
And I'm just thinking there's probably so many people like me who are in this stage of their life where they're in cities working really hard, either working from home or in an office, and they just don't have access to what you have access to
This formulation achieved 20.7% weight loss in trials, narrowing the gap between existing Ozempic/Wegovy and Retatrutide
